CORONA Remedies: Q4 FY26 Earnings Call Audio Available Online
CORONA Remedies Limited has released the audio recording of its conference call discussing Q4 and FY26 financial results. The recording is available on the company's website.
The release of an audio recording of a previously held conference call is a standard disclosure and is unlikely to have a significant impact on the company's stock or investor decisions.
The announcement is a routine disclosure of a conference call recording and does not contain new financial information or significant company developments that would sway sentiment.
CORONA Remedies Limited has made the audio recording of its conference call with analysts and investors publicly available. The call discussed the company's audited financial results for the fourth quarter and the full year ended March 31, 2026.
The recording can be accessed on the company's official website at https://www.coronaremedies.com/q4fy26-earnings-call-audio. This announcement follows up on a previous letter dated April 30, 2026, and complies with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Chetna Dharajiya, Company Secretary and Compliance Officer, signed off on the disclosure.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.